Circa Pharmaceuticals
Executive Summary
Pleads nolo contendere Oct. 20 in Baltimore federal court to price-fixing charge. Circa (formerly Bolar) and its VP-Financial Affairs Lawrence Raisfeld, were charged last December with conspiring with Vitarine Pharmaceuticals to fix the price of generic Dyazide ("The Pink Sheet" Dec. 21, 1992, p. 17). Raisfeld also pled no contest and was fined $20,000. Circa paid the government $1 mil. and will now defend civil actions brought by General Generics and Spawd, Inc. Those suits were stayed pending the resolution of the criminal case.